Elite in Primary Amyloidosis

Giovanni Palladini

Pavia, IT 
Elite in Primary Amyloidosis
Pavia, IT 
OverviewLocationsClinical Research

Overview

Giovanni Palladini practices in Pavia, Italy. Mr. Palladini is rated as an Elite expert by MediFind in the treatment of Primary Amyloidosis. His top areas of expertise are Primary Amyloidosis, Cardiac Amyloidosis, Transthyretin Amyloidosis, Tissue Biopsy, and Bone Marrow Transplant.

His clinical research consists of co-authoring 235 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 217 articles and participated in 4 clinical trials in the study of Primary Amyloidosis.

Gender
Male

Locations

Pavia, Italy
Other Locations
San Matteo, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Prognostic Value of Phase Angle in Systemic Immunoglobulin Light-chain (AL) Amyloidosis
Prognostic Value of Phase Angle in Systemic Immunoglobulin Light-chain (AL) Amyloidosis
Enrollment Status: Completed
Publish Date: May 01, 2025
Intervention Type: Other
Phase 2 Study of Daratumumab Monotherapy in Previously Untreated Patients With Stage 3B Light Chain (AL) Amyloidosis
Phase 2 Study of Daratumumab Monotherapy in Previously Untreated Patients With Stage 3B Light Chain (AL) Amyloidosis
Enrollment Status: Completed
Publish Date: April 16, 2025
Intervention Type: Drug
Study Drugs: Daratumumab, Bortezomib Injection, Dexamethasone oral tablet
Study Phase: Phase 2
An Open-Label, Phase 1/2 Study of Melflufen and Dexamethasone for Patients With AL Amyloidosis Following at Least One Prior Line of Therapy
An Open-Label, Phase 1/2 Study of Melflufen and Dexamethasone for Patients With AL Amyloidosis Following at Least One Prior Line of Therapy
Enrollment Status: Terminated
Publish Date: March 28, 2022
Intervention Type: Drug
Study Drugs: Melphalan-Flufenamide (Melflufen), Dexamethasone
Study Phase: Phase 1
A Phase II Open-label Randomized Study of Dietary Supplement With Epigallocatechin Gallate (EGCG) to Improve Cardiac Dysfunction in Patients With AL Amyloidosis Who do Not Require Chemotherapy (EpiCardiAL)
A Phase II Open-label Randomized Study of Dietary Supplement With Epigallocatechin Gallate (EGCG) to Improve Cardiac Dysfunction in Patients With AL Amyloidosis Who do Not Require Chemotherapy (EpiCardiAL)
Enrollment Status: Terminated
Publish Date: March 21, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 3 Less Clinical Trials

234 Total Publications

A new validated staging system for AL amyloidosis with Stage IIIC defining ultra-poor risk: AL International Staging System (AL-ISS).
A new validated staging system for AL amyloidosis with Stage IIIC defining ultra-poor risk: AL International Staging System (AL-ISS).
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 07, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Palladini's expertise for a condition
ConditionClose
View All 13 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile